Key result
Mibefradil was effective for the symptomatic treatment of hypertension and stable angina pectoris but was withdrawn due to drug interactions at the cytochrome P-450 3A4 enzyme.
Mibefradil showed promise for hypertension and angina but was withdrawn due to CYP3A4 interactions, leaving T-channel blockade as an area for future drug development.
Answers are grounded in this paper and cite their sources.
Mibefradil's CYP3A4 interactions warrant ongoing caution; leaves open selective T-channel blockade for hypertension and angina research.
Basic studies as well as short-term clinical trials of the T-channel-selective calcium channel blocker, mibefradil, are reviewed. The compound reduced afterload and was effective for the symptomatic treatment of hypertension and stable angina pectoris. It did not display any relevant negative inotropic or positive chronotropic effect. Mibefradil has been withdrawn by the manufacturer because of drug interaction at the cytochrome P-450 3A4 enzyme. It is hoped that new T-channel-selective calcium channel blockers will be developed to explore further this promising but so far only preliminarily tested therapeutic possibility.
No takes yet. Share an insight, caveat, or question.
Vring et al. (1999) conducted a review in Hypertension and stable angina pectoris. Mibefradil was evaluated. Mibefradil was effective for the symptomatic treatment of hypertension and stable angina pectoris but was withdrawn due to drug interactions at the cytochrome P-450 3A4 enzyme.
Synapse has enriched 10 related papers. Consider them for comparative context: